A phase 2 clinical trial of preoperative pembrolizumab and chemotherapy followed by adjuvant pembrolizumab in resectable locoregionally recurrent head and neck squamous cell carcinoma. This is an ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results